Table 1.
Half-maximal inhibitory concentrations (IC50) values for single RBD-chAbs against pseudoviruses of SARS-CoV-2 variants
| SARS-CoV-2 pseudovirus IC50 (ng/ml) | ||||
|---|---|---|---|---|
| D614G | B.1.1.7 (UK, Alpha) |
B.1.351 (SA, Beta) |
P1 (Brazil, Gamma) |
|
| RBD-chAb-1 | 24.35 ± 5.55 | 33.46 ± 17.9 | 46.71 ± 10.98 | 17.09 ± 7.72 |
| RBD-chAb-15 | 21.25 ± 11.13 | 39.73 ± 16.66 | 30.13 ± 12.03 | 7.18 ± 5.46 |
| RBD-chAb-25 | 9.92 ± 2.04 | Non-N | Non-N | Non-N |
| RBD-chAb-28 | 9.55 ± 4.16 | 11.29 ± 5.93 | 16.52 ± 6.03 | 4.18 ± 1.80 |
| RBD-chAb-45 | 1.58 ± 0.54 | 2.06 ± 0.58 | 2.68 ± 0.84 | 0.76 ± 0.14 |
| RBD-chAb-51 | 1.30 ± 0.27 | 3.07 ± 0.72 | 1.26 ± 0.58 | 0.70 ± 0.19 |
| SARS-CoV-2 pseudovirus IC50 (ng/ml) | ||||
|---|---|---|---|---|
| B.1.429 (California, Epsilon) |
B.1.526 (NY, Iota) |
B.1.617.1 (India, Kappa) |
B.1.617.2 (India, Delta) |
|
| RBD-chAb-1 | 21.6 ± 11.13 | 428.2 ± 166.3 | 117.7 ± 55.64 | 429.3 ± 36.55 |
| RBD-chAb-15 | 11.72 ± 5.40 | 87.89 ± 5.09 | 67.71 ± 15.84 | 103.6 ± 16.57 |
| RBD-chAb-25 | 6.51 ± 0.73 | 91.95 ± 66.85 | 42.27 ± 7.27 | 35.5 ± 12.14 |
| RBD-chAb-28 | 3.28 ± 1.71 | 44.07 ± 29.58 | 60.62 ± 37.4 | 94.13 ± 22.07 |
| RBD-chAb-45 | 0.91 ± 0.16 | 4.23 ± 1.51 | 5.95 ± 0.72 | 15.51 ± 4.58 |
| RBD-chAb-51 | 1.32 ± 0.75 | 2.28 ± 0.08 | 4.55 ± 1.2 | 8.04 ± 2.11 |
Data are from three independent experiments and are shown as mean ± SEM
Non-N non-neutralizing